1672 — Ascletis Pharma Share Price
0.000.00%
Last trade - 00:00- HK$6.05bn
- HK$3.98bn
- CNY1.28m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.89 | ||
| Price to Tang. Book | 2.91 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4,427.05 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -14.98% | ||
| Return on Equity | -13.97% | ||
| Operating Margin | -23025.64% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 35 | 76.88 | 54.09 | 56.6 | 1.28 | n/a | 207.6 | -62.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ascletis Pharma Inc is a China-based investment holding company principally engaged in the research, development, production, marketing and sales of pharmaceutical products. The Company mainly focuses on viral diseases, non-alcoholic steatohepatitis (NASH) and oncology fields. Viral diseases pipeline includes Ritonavir, Ravidasvir, Danoprevir and others. NASH pipeline includes ASC40, ASC41, ASC42 and others. Oncology pipeline includes ASC60, ASC61 and others.
Directors
- Jinzi Jason Wu CHM
- Handan He CSO
- Judy Hejingdao Wu VPR (44)
- Yuemei Yan VPR (48)
- Yi Chen VPR (54)
- Lok Kwan Yim SEC
- Jiong Gu NID (48)
- Lin Hua NID (44)
- Yizhen Wei NID (43)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 25th, 2014
- Public Since
- August 1st, 2018
- No. of Employees
- 231
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 963,111,793
- Address
- 12F, Building D, HANGZHOU
- Web
- https://www.ascletis.com/
- Phone
- Auditors
- KPMG
Upcoming Events for 1672
Similar to 1672
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Co
Stock Exchange of Hong Kong Limited
FAQ
What is the Ascletis Pharma share price?
As of Today at 01:21 UTC, shares in Ascletis Pharma are trading at HK$6.28. This share price information is delayed by 15 minutes.
How has the Ascletis Pharma share price performed this year?
Shares in Ascletis Pharma last closed at HK$6.28 and the price had moved by +361.76% over the past 365 days. In terms of relative price strength the Ascletis Pharma share price has outperformed the FTSE Developed Asia Pacific Index by +367.04% over the past year.
What are the analyst and broker recommendations for Ascletis Pharma?
The overall consensus recommendation for Ascletis Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ascletis Pharma dividend yield?
Ascletis Pharma does not currently pay a dividend.
Does Ascletis Pharma pay a dividend?
Ascletis Pharma does not currently pay a dividend.
When does Ascletis Pharma next pay dividends?
Ascletis Pharma does not currently pay a dividend.
How do I buy Ascletis Pharma shares?
To buy shares in Ascletis Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ascletis Pharma?
As of the previous close price of HK$6.28, shares in Ascletis Pharma had a market capitalisation of HK$6.05bn.
Where are Ascletis Pharma shares listed?
Here are the trading details for Ascletis Pharma:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1672
What kind of share is Ascletis Pharma?
Based on an overall assessment of its quality, value and momentum Ascletis Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ascletis Pharma share price forecast for 2025?
The analyst consensus target price for shares in Ascletis Pharma is HK$4.92. That is 21.58% below the last closing price of HK$6.28.
Analysts covering Ascletis Pharma currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.40 for the next financial year.
Find out moreWhat is the trend in the Ascletis Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ascletis Pharma. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +382.21%.
As of the last closing price of HK$6.28, shares in Ascletis Pharma were trading +110.51% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ascletis Pharma PE Ratio?
The Ascletis Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$6.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ascletis Pharma?
Ascletis Pharma's management team is headed by:
- Jinzi Jason Wu - CHM
- Handan He - CSO
- Judy Hejingdao Wu - VPR
- Yuemei Yan - VPR
- Yi Chen - VPR
- Lok Kwan Yim - SEC
- Jiong Gu - NID
- Lin Hua - NID
- Yizhen Wei - NID